OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Medical Economics is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
The economic impact of suboptimal treatment and treatment switch among patients with Crohn’s disease treated with a first-line biologic – A US retrospective claims database study	92
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in	68
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsych	51
Micro-costing of genetic diagnostics in acute leukemia in Sweden: from standard-of-care to whole-genome sequencing	49
Health care resource utilization in the management of patients with Arginase 1 Deficiency in the US: a retrospective, observational, claims database study	37
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States	34
Levalbuterol vs. albuterol for hospitalized patients with COPD in China: cost-utility and budget impact analysis	32
The economic burden of systemic lupus erythematosus in Taiwan	31
Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermedi	30
Economic burden of respiratory syncytial virus infection in adults: a systematic literature review	30
The economic impact of tobacco smoking and secondhand smoke exposure in Jordan: estimating the direct and indirect costs	28
Initiating immunoglobulin replacement therapy helps reduce severe infections and shifts healthcare resource utilization to outpatient services among US patients with inborn errors of immunity	27
Challenges in health economics research: insights from real-world examples	27
Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries	27
The impact of diagnosing provider type on longitudinal care for patients with newly diagnosed Huntington’s disease	26
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment	25
Identification of cancer chemotherapy regimens and patient cohorts in administrative claims: challenges, opportunities, and a proposed algorithm	23
Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective	22
Cost-effectiveness analysis of carbetocin versus oxytocin for the prevention of postpartum hemorrhage following vaginal birth in the United Kingdom	20
Utilities associated with stoma-related complications: peristomal skin complications and leakages	19
Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries	19